Saturday, October 25, 2025

Aurora Cannabis: Canaccord Anticipates Q2 Revenues Of $69.5 Million

On Thursday, February 11th, Aurora Cannabis (TSX: ACB) (NYSE: ACB) is scheduled to release their second fiscal quarter 2021 financial results.

Aurora currently has 13 analysts covering the company with a weighted 12-month price target of C$11.95. This is up slightly from last month, which was C$11.41. Ten analysts have hold ratings, while one analyst has a sell rating and two have strong sell ratings on Aurora.

Matt Bottomley expects that Aurora’s results will be relatively flat. He writes that although Canada’s sale numbers have almost consistently hit all-time highs every month and Ontario is pushing out stores at 2x the normal rates, “we believe the economics captured by LPs will be slightly more muted due to saturated inventory balances held in provincial wholesale channels and the potential for continued infrastructure/inventory write-offs.”

He also believes that the product mix will still be value priced flower and not premium or 2.0 products, which will hurt Aurora’s overall growth for the quarter.

Bottomley forecasts Aurora’s net revenues will be C$69.5 million, or a modest 2.5% increase quarter over quarter. Of that, C$46.6 million is expected to come from Canadian adult use. He says that this is flat as, “the company continues to pivot toward a more ‘premium’ product strategy vs. its historical reliance on value priced bud.”

Bottomley also expects that Aurora’s increased product offerings will fall short in the near term as the company faces more headwinds.

Everything is not doom and gloom however, with Bottomley forecasting that Aurora remains the market leader in Canadian medical as they estimate the segment to generate C$38 million in revenues for the quarter.

Bottomley expects adjusted gross margin to be 52%, but says that after Aurora Sun’s closures and the drop in utilization at Aurora Sky that adjusted gross margin will be more like 45%. Bottomley writes, “we would not be surprised to see sizable impairment charges on the back of these closures.” Bottomley forecasts Aurora’s second-quarter EBITDA loss to come in at C$7.2 million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver at $100? This Time It Might Stay There. | David Morgan

Critical Minerals Are Rerating! | John Passalacqua – First Phosphate

This Isn’t A Gold Rally. It’s A Warning! | Adrian Day

Recommended

Steadright Enters MOU To Acquire Historic Goundafa Polymetallic Mine In Morocco

Military Seizes Power in Madagascar After President Flees

Related News

Hexo Corp: Canaccord Cuts Target To $0.25 After Guidance Withdrawal

Earlier this week Hexo Corp (TSX: HEXO) reported its fiscal third-quarter ending April 30th. The...

Thursday, June 16, 2022, 04:32:00 PM

Eldorado Gold: BMO Reiterates $20 Price Target After Skouries Feasibility Study

On December 15th, Eldorado Gold (TSX: ELD) announced the results of the Skouries Project feasibility...

Monday, December 27, 2021, 11:04:00 AM

Osisko Gold Royalties Sees BMO Reiterate $17 Price Target

On July 12, Osisko Gold Royalties (TSX: OR) announced their preliminary second-quarter deliveries, revenues, and...

Thursday, July 14, 2022, 10:56:00 AM

Curaleaf Sees Consensus Estimates Stay Flat After Q1 Results

Curaleaf Holdings (CSE: CURA) reported its first-quarter results on May 10th, beating the consensus estimates...

Saturday, May 15, 2021, 04:24:00 PM

Plant 13: Canaccord Lowers Estimates Due To COVID Headwinds

On August 26, Planet 13 Holdings (CSE: PLTH) announced its second quarter financial results. The...

Monday, August 30, 2021, 04:49:00 PM